{
    "clinical_study": {
        "@rank": "116124", 
        "arm_group": [
            {
                "arm_group_label": "Lomitapide & EE/Norgestimate - Taken Together", 
                "arm_group_type": "Experimental", 
                "description": "2 single oral doses of lomitapide (20 mg) (Day 1 & Day 22)\n21 single oral doses of EE/Norgestimate(Day 8 through day 28)"
            }, 
            {
                "arm_group_label": "Lomitapide & EE/Norgestimate - Taken 12 hours apart", 
                "arm_group_type": "Experimental", 
                "description": "2 single oral doses of lomitapide (20 mg) (Day 1 & Day 22)\n21 single oral doses of EE/Norgestimate(Day 9 through day 29)"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to assess the effect of ethinyl estradiol\n      (EE)/norgestimate, a weak cytochrome P450 (CYP) 3A4 inhibitor, on the pharmacokinetics (PK)\n      of lomitapide and 2 primary metabolites, M1 and M3."
        }, 
        "brief_title": "Evaluate the Effect of Ethinyl Estradiol/Norgestimate on the Pharmacokinetics of Lomitapide in Healthy Female Subjects", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "This study will be a single center, randomized, open-label, 2 arm study to evaluate the\n      effects of EE/norgestimate, a weak CYP3A4 inhibitor, on the PK of lomitapide in healthy\n      female subjects when EE/norgestimate is administered simultaneously with lomitapide and when\n      administration is separated by 12 hours."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy females, between 18 and 40 years of age inclusive\n\n          2. BMI between 18.5 and 32.0 kg/m2, inclusive; total body weight of >110 lbs (50 kg);\n\n          3. in good health, determined by no clinically significant or relevant abnormalities\n             identified by a detailed medical history\n\n          4. no known history of hypersensitivity or previous intolerance to lomitapide or\n             EE/norgestimate\n\n          5. creatine phosphokinase, AST, and ALT levels must be below 1.5 times the upper limit\n             of normal\n\n          6. clinical laboratory evaluations within the reference range for the test laboratory\n\n          7. negative test for selected drugs of abuse\n\n          8. negative hepatitis panel and negative HIV antibody screens\n\n          9. are of childbearing potential(ie, not postmenopausal or surgically sterile).  All\n             subjects must have a negative serum beta pregnancy test.\n\n         10. able to comprehend and willing to sign an Informed Consent Form\n\n        Exclusion Criteria:\n\n          1. significant history or clinical manifestation of any metabolic, allergic,\n             dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, GI,\n             neurological, or psychiatric disorder\n\n          2. history of unexplained breast abnormalities or abnormal uterine bleeding\n\n          3. history of significant hypersensitivity, intolerance, or allergy to any drug\n             compound, food, or other substance\n\n          4. history of stomach or intestinal surgery or resection\n\n          5. history of Gilbert's Syndrome or suspicion of Gilbert's Syndrome\n\n          6. subjects who have an abnormality in the 12-lead ECG\n\n          7. use of any drugs of abuse for 6 months prior to Check-in;\n\n          8. subjects who consume more than 14 units of alcohol per week or who have a significant\n             history of alcoholism or drug/chemical abuse within 1 year prior to Check-in\n\n          9. use of any tobacco- or nicotine-containing products  within 6 months prior to\n             Check-in;\n\n         10. participation in any other investigational study drug trial within 30 days prior to\n             Check-in;\n\n         11. use of any prescription medications/products within 14 days prior to Check-in unless\n             deemed acceptable by the Investigator and Sponsor\n\n         12. use of any over-the-counter, nonprescription preparations within 7 days prior to\n             Check-in, unless deemed acceptable by the Investigator and Sponsor\n\n         13. use of alcohol-, grapefruit- (including star fruit), or caffeine-containing foods or\n             beverages within 72 hours prior to Check-in and through Study Completion\n\n         14. use of oral (except scheduled administration of EE/norgestimate), implantable,\n             injectable, or transdermal contraceptives\n\n         15. use of hormone replacement therapy\n\n         16. poor peripheral venous access;\n\n         17. donation of blood (500 mL) from 30 days prior to Screening through Study Completion\n\n         18. receipt of blood products within 2 months prior to Check-in;\n\n         19. any acute or chronic condition, scheduled hospitalization (inclusive of elective\n             surgery during study) or scheduled travel prior to completion of all study procedures\n             which, in the opinion of the Investigator, would limit the subject's ability to\n             complete and/or participate in this clinical study;\n\n         20. subjects who, in the opinion of the Investigator, should not participate in this\n             study."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02080468", 
            "org_study_id": "AEGR-733-029"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Lomitapide & EE/Norgestimate - Taken Together", 
                    "Lomitapide & EE/Norgestimate - Taken 12 hours apart"
                ], 
                "description": "20 mg", 
                "intervention_name": "lomitapide", 
                "intervention_type": "Drug", 
                "other_name": "Juxtapid"
            }, 
            {
                "arm_group_label": [
                    "Lomitapide & EE/Norgestimate - Taken Together", 
                    "Lomitapide & EE/Norgestimate - Taken 12 hours apart"
                ], 
                "description": "1x0.035-mg EE/0.25-mg norgestimate tablet", 
                "intervention_name": "EE/norgestimate", 
                "intervention_type": "Drug", 
                "other_name": "Ortho Cylclen"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Estradiol", 
                "Polyestradiol phosphate", 
                "Ethinyl Estradiol", 
                "Estradiol valerate", 
                "Estradiol 3-benzoate", 
                "Estradiol 17 beta-cypionate", 
                "Norgestimate", 
                "Norgestrel", 
                "Norgestimate, ethinyl estradiol drug combination", 
                "Moxifloxacin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Effect", 
            "Ethinyl Estradiol/Norgestimate", 
            "Pharmacokinetics", 
            "Lomitapide."
        ], 
        "lastchanged_date": "April 30, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75247"
                }, 
                "name": "Covance Clinical Research Unit, Inc"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Open-Label, Randomized, 2-Arm Study to Evaluate the Effect of Ethinyl Estradiol/Norgestimate (Ortho Cyclen\u00ae), a Weak CYP3A4 Inhibitor, on the Pharmacokinetics of Lomitapide in Healthy Female Subjects", 
        "overall_official": [
            {
                "affiliation": "Cheif Medical Officer", 
                "last_name": "Mark Sumeray, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Covance Clinical Research Unit Inc.", 
                "last_name": "T. Alex King, MD, CPI", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "area under the concentration-time curve from 0 to the last measurable concentration", 
            "measure": "AUC0-t", 
            "safety_issue": "No", 
            "time_frame": "predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02080468"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "time to maximum concentration", 
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing."
            }, 
            {
                "description": "time to maximum observed concentration", 
                "measure": "tmax", 
                "safety_issue": "No", 
                "time_frame": "Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing."
            }, 
            {
                "description": "apparent terminal elimination half-life", 
                "measure": "t1/2", 
                "safety_issue": "No", 
                "time_frame": "Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing."
            }, 
            {
                "description": "area under the concentration-time curve extrapolated to infinity", 
                "measure": "AUC0-\u221e", 
                "safety_issue": "No", 
                "time_frame": "Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing."
            }, 
            {
                "description": "apparent terminal elimination rate constant", 
                "measure": "\u03bbz", 
                "safety_issue": "No", 
                "time_frame": "Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing."
            }
        ], 
        "source": "Aegerion Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Aegerion Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}